Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 83Pancreatic Neoplasms 33Stomach Neoplasms 32Rectal Neoplasms 23Colonic Neoplasms 22Neoplasms 20Neoplasm Metastasis 19Esophageal Neoplasms 16Cholangiocarcinoma 14Adenocarcinoma Of Esophagus 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Non-Small-Cell Lung 12Burkitt Lymphoma 12Biliary Tract Neoplasms 12Adenocarcinoma 11Gastrointestinal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 6Leukemia, Biphenotypic, Acute 5Gallbladder Neoplasms 5Esophageal Squamous Cell Carcinoma 5Endometrial Neoplasms 5Advanced Solid Tumors 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lung Neoplasms 4Leukemia 4Carcinoma, Renal Cell 4Appendiceal Neoplasms 4Urinary Bladder Neoplasms 3

Interventions

Nivolumab 2talimogene laherparepvec 1Specimen Handling 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Signet Ring Cell × Leucovorin × 1 year × Clear all
NCT05504252 2026-01-07

METIMMOX-2

University Hospital, Akershus

Phase 2 Active not recruiting
80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡